Appointed
Kelly Wei
Director
NVEC ·
NVE CORP /NEW/
the NVE Board of Directors elected Kelly Wei, Ph.D. to join the Board effective May 13, 2024.
Ready 8-Ks
17
Latest filing
May 6, 2026, 7:59 PM ET
Top materiality
0.80
Event mix
earnings ×10 · other_material ×4 · other ×2
Sentiment
4 pos · 5 neg · 8 neu
Latest earnings
reported 2026-FY
Executive change
recent →
Recent 8-K filings for NVEC
Highest-materiality recent filing
NVE Q4 revenue $7.08M (-45%), EPS $0.79; FY revenue $29.8M (-22%); declares $1.00 dividend
- Q4 revenue $7.08M (-45% YoY); net income $3.81M ($0.79 EPS) down 54%.
- FY2024 revenue $29.8M (-22% YoY); net income $17.1M ($3.54 EPS) down 25%.
-
NVE Q4 revenue up 5% to $7.65M, EPS $1.02; declares $1.00 dividend
Q4 revenue $7.65M (+5% YoY); product sales up 6%, contract R&D down 19%.
-
NVE reports Q3 revenue up 23% to $6.22M, EPS $0.70 (+11% YoY); declares $1.00 dividend
Q3 total revenue $6.22M, up 23% from $5.06M; product sales +16%, contract R&D +335%.
-
NVE extends Abbott supply agreement through 2027 with pricing increases for 2026-2027
Amendment No. 12 to Supplier Partnering Agreement with Pacesetter (Abbott) executed Dec 12, 2025.
-
NVE Q2 revenue down 6% to $6.35M; EPS $0.68 vs $0.83; declares $1.00 dividend
Total revenue $6.35M, down 6% YoY; product sales +1%, contract R&D -68%.
-
All five director nominees elected: Glarner, Baker, Hollister, Bracke, Wei each received >2.98M votes with minimal withhold.
-
NVE Q1 revenue down 10% to $6.10M; EPS $0.74 vs $0.85; declares $1.00 dividend
Revenue $6.10M (down 10% YoY), net income $3.58M (down 13%); diluted EPS $0.74.
-
NVE Q4 revenue up 3% to $7.27M, EPS $0.80; full-year revenue down 13%; $1.00 dividend declared
Q4 revenue $7.27M (+3% YoY); net income $3.89M ($0.80 EPS) vs $3.81M ($0.79).
-
Amendment No. 11 extends Supplier Partnering Agreement term to December 31, 2025.
-
NVE Q3 revenue down 25% to $5.06M, net income falls 27% to $0.63 EPS; $1.00 dividend declared
Q3 total revenue $5.06M, down 25% YoY; product sales fell 22% and contract R&D revenue dropped 74%.
-
NVE extends office/manufacturing lease to May 2031 with escalating rent
Lease extended 62 months, new expiration May 31, 2031 (originally March 31, 2026).
-
NVE Q2 revenue down 5% to $6.76M; EPS $0.83 vs $0.98; declares $1.00 dividend
Total revenue for Q2 FY2025: $6.76M, down 5% from $7.13M; product sales fell 14%, contract R&D surged 3,950%.
-
NVE shareholders elect all five directors, approve say-on-pay, ratify auditor
All five director nominees elected: Glarner (2.78M for), Baker (3.06M), Hollister (2.85M), Bracke (3.05M), Wei (3.06M).
-
NVE reports Q1 revenue down 23% to $6.78M, EPS $0.85 vs $0.91 prior year
Total revenue $6.78M, down 23% YoY; product sales fell 24%, contract R&D up 28%.
-
NVE director Richard Kramp dies; Dr. Kelly Wei elected to board
Director Richard W. Kramp passed away May 2, 2024 after an illness; served on NVE board since 2014.
-
NVE Q4 revenue $7.08M (-45%), EPS $0.79; FY revenue $29.8M (-22%); declares $1.00 dividend
Q4 revenue $7.08M (-45% YoY); net income $3.81M ($0.79 EPS) down 54%.
-
NVE Q3 revenue down 9% to $6.76M; net income down 1% to $4.18M; declares $1/share dividend
Total revenue for quarter ended Dec 31, 2023: $6.76M, down 9% vs $7.40M prior year. Product sales down 12%; contract R&D up 94%.
-
NVE extends Abbott supply pact through Dec 2024 with price increases
Amendment No. 10 extends Supplier Partnering Agreement with Abbott subsidiary Pacesetter through December 31, 2024.
Executive changes
Departed
Richard W. Kramp
Director
NVEC ·
NVE CORP /NEW/
Director Richard W. Kramp passed away on May 2, 2024.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.80 · Median 0.55 · Most common event earnings